Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended	9 Months Ended
Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Operating expenses:
Research and development	$ 4,464	$ 1,979	$ 10,200	$ 6,345
General and administrative	1,435	1,498	5,196	5,351
Total operating expenses	5,899	3,477	15,396	11,696
Total operating loss	(5,899)	(3,477)	(15,396)	(11,696)
Other income (expense):
Interest income	12	12	40	29
Loss from equity method investment in Galectin Sciences, LLC		(53)		(390)
Total other income (expense)	12	(41)	40	(361)
Net loss	(5,887)	(3,518)	(15,356)	(12,057)
Preferred stock dividends	(208)	(278)	(629)	(763)
Preferred stock accretion	(57)	(57)	(172)	(172)
Net loss applicable to common stockholders	$ (6,152)	$ (3,853)	$ (16,157)	$ (12,992)
Net loss per common share - basic and diluted	$ (0.26)	$ (0.17)	$ (0.69)	$ (0.60)
Weighted average common shares outstanding - basic and diluted	23,793	22,051	23,531	21,732

The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements. Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period. Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

No definition available.